CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 24 enrolled
Drug / intervention
REMSA +1 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02710487
NCT02710487N/ACompleted
CompareCT.gov

Awake & Move. Role of Nocturnal Sleep and Rapid Eye Movement Sleep at Morning Awakening on Sleep Benefit in Parkinson's Disease. An Interventional Cross-over Study.

Neurocenter of Southern Switzerland·interventional·Posted Mar 16, 2016·Updated Aug 27, 2018

In Brief

A clinical study evaluating REMSA and NREMSA for Idiopathic Parkinson's Disease. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Sleep benefit (SB) is a prominent spontaneous, apparently unpredictable, transitory improvement in motor function reported by around 50% of patients affected by Parkinson's Disease (PD) after sleep and before taking their first dose of dopaminergic medications. The aim of this study is to test the hypothesis that objective and/or subjective improvement of motor function might be due to a carry-over effect of Rapid Eye Movements (REM) sleep at awakening from this sleep phase.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Parkinson's Disease
CountriesSwitzerland
CollaboratorsParkinson Schweiz, Ente Ospedaliero Cantonale, Bellinzona, Penn State University

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 16, 2016
Enrollment StartMar 3, 2016
Primary CompletionJan 12, 2018
Study CompletionJul 27, 2018
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 10.3 years ago

Interventions

REMSAbehavioral

Awakening from REM sleep during the last hour of the sleep period

NREMSAbehavioral

Awakening from N2 (NREM) sleep during the last hour of the sleep period